Alnylam Pharmaceuticals (ALNY) Set to Announce Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is anticipated to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.66 per share and revenue of $1.43 billion for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the firm earned ($0.51) EPS. The business’s revenue was up 66.9% on a year-over-year basis. On average, analysts expect Alnylam Pharmaceuticals to post $6.43 EPS for the current fiscal year and $9.24 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ ALNY opened at $227.66 on Tuesday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a 52 week low of $197.81 and a 52 week high of $485.36. The firm has a 50-day moving average price of $239.03 and a 200 day moving average price of $290.16. The stock has a market capitalization of $30.46 billion, a price-to-earnings ratio of 42.32 and a beta of 0.28.

Insider Activity

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Oppenheimer dropped their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Sanford C. Bernstein reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Royal Bank Of Canada dropped their price target on Alnylam Pharmaceuticals from $350.00 to $345.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Finally, Truist Financial cut their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $364.95.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.